TrialEuropean journal of neurology2022

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.

Gavin Giovannoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.